137 related articles for article (PubMed ID: 36229048)
21. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
22. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study.
Burmester GR; Feist E; Sleeman MA; Wang B; White B; Magrini F
Ann Rheum Dis; 2011 Sep; 70(9):1542-9. PubMed ID: 21613310
[TBL] [Abstract][Full Text] [Related]
23. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
Stone RM; Berg DT; George SL; Dodge RK; Paciucci PA; Schulman P; Lee EJ; Moore JO; Powell BL; Schiffer CA
N Engl J Med; 1995 Jun; 332(25):1671-7. PubMed ID: 7760868
[TBL] [Abstract][Full Text] [Related]
24. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.
Meisel C; Schefold JC; Pschowski R; Baumann T; Hetzger K; Gregor J; Weber-Carstens S; Hasper D; Keh D; Zuckermann H; Reinke P; Volk HD
Am J Respir Crit Care Med; 2009 Oct; 180(7):640-8. PubMed ID: 19590022
[TBL] [Abstract][Full Text] [Related]
25. Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.
Guo X; Higgs BW; Bay-Jensen AC; Wu Y; Karsdal MA; Kuziora M; Godwood A; Close D; Ryan PC; Roskos LK; White WI
Rheumatology (Oxford); 2018 Jan; 57(1):175-184. PubMed ID: 29069507
[TBL] [Abstract][Full Text] [Related]
26. Effect of progenitor cell mobilization with granulocyte-macrophage colony-stimulating factor in patients with peripheral artery disease: a randomized clinical trial.
Poole J; Mavromatis K; Binongo JN; Khan A; Li Q; Khayata M; Rocco E; Topel M; Zhang X; Brown C; Corriere MA; Murrow J; Sher S; Clement S; Ashraf K; Rashed A; Kabbany T; Neuman R; Morris A; Ali A; Hayek S; Oshinski J; Yoon YS; Waller EK; Quyyumi AA
JAMA; 2013 Dec; 310(24):2631-9. PubMed ID: 24247554
[TBL] [Abstract][Full Text] [Related]
27. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis.
Bo L; Wang F; Zhu J; Li J; Deng X
Crit Care; 2011; 15(1):R58. PubMed ID: 21310070
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group
Lancet Infect Dis; 2022 May; 22(5):622-635. PubMed ID: 34953520
[TBL] [Abstract][Full Text] [Related]
29. Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial.
Gorin NC; Coiffier B; Hayat M; Fouillard L; Kuentz M; Flesch M; Colombat P; Boivin P; Slavin S; Philip T
Blood; 1992 Sep; 80(5):1149-57. PubMed ID: 1515637
[TBL] [Abstract][Full Text] [Related]
30. Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects.
Crotti C; Agape E; Becciolini A; Biggioggero M; Favalli EG
Drugs; 2019 Nov; 79(16):1741-1755. PubMed ID: 31486005
[TBL] [Abstract][Full Text] [Related]
31. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
[TBL] [Abstract][Full Text] [Related]
32. A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury.
Paine R; Standiford TJ; Dechert RE; Moss M; Martin GS; Rosenberg AL; Thannickal VJ; Burnham EL; Brown MB; Hyzy RC
Crit Care Med; 2012 Jan; 40(1):90-7. PubMed ID: 21926600
[TBL] [Abstract][Full Text] [Related]
33. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
[TBL] [Abstract][Full Text] [Related]
34. Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial.
Les Bujanda I; Loureiro-Amigo J; Bastons FC; Guerra IE; Sánchez JA; Murgadella-Sancho A; Rey RG; López JL; Álvarez JS
Trials; 2021 Jan; 22(1):43. PubMed ID: 33430891
[TBL] [Abstract][Full Text] [Related]
35. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.
Lescure FX; Honda H; Fowler RA; Lazar JS; Shi G; Wung P; Patel N; Hagino O;
Lancet Respir Med; 2021 May; 9(5):522-532. PubMed ID: 33676590
[TBL] [Abstract][Full Text] [Related]
36. A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma.
de Vries EG; Biesma B; Willemse PH; Mulder NH; Stern AC; Aalders JG; Vellenga E
Cancer Res; 1991 Jan; 51(1):116-22. PubMed ID: 1988077
[TBL] [Abstract][Full Text] [Related]
37. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction.
Presneill JJ; Harris T; Stewart AG; Cade JF; Wilson JW
Am J Respir Crit Care Med; 2002 Jul; 166(2):138-43. PubMed ID: 12119223
[TBL] [Abstract][Full Text] [Related]
38. Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome.
Perlin DS; Neil GA; Anderson C; Zafir-Lavie I; Raines S; Ware CF; Wilkins HJ
J Clin Invest; 2022 Feb; 132(3):. PubMed ID: 34871182
[TBL] [Abstract][Full Text] [Related]
39. Sargramostim (GM-CSF) for induction of remission in Crohn's disease.
Roth L; Macdonald JK; McDonald JW; Chande N
Cochrane Database Syst Rev; 2011 Nov; (11):CD008538. PubMed ID: 22071853
[TBL] [Abstract][Full Text] [Related]
40. Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes.
Verbeek W; Wörmann B; Koch P; Aul C; Hinrichs HF; Balleisen L; Rowe JM; Bennett J; Haase D; Fonatsch C; Heinecke A; Büchner T; Hiddemann W
J Cancer Res Clin Oncol; 1999; 125(6):369-74. PubMed ID: 10363570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]